Efficacy of Sarilumab

Sarilumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who are responsive to one or more disease-modifying antirheumatic drugs (DMARDs). ), and adult patients with polymyalgia rheumatica (PMR) who have an inadequate response to corticosteroids or cannot tolerate a reduction in corticosteroids. A single dose of subcutaneous injection of salizumab can rapidly reduce CRP levels, reaching normal levels after two weeks of treatment.

Salirumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptor (IL-6R), thereby inhibiting IL-6-mediated signaling. IL-6 is a pleiotropic cytokine that activates immune cells (T and B cells) and hepatocytes to release acute phase proteins such as CRP, serum amyloid A, and fibrinogen, which are biomarkers of rheumatoid arthritis (RA) activity. IL-6 is also present in synovial fluid and plays a major role in the pathological inflammation and joint destruction characteristic of RA. Therefore, it is used to treat rheumatoid arthritis due to its ability to inhibit intra-articular and systemic IL-6 signaling.

The patent drug of Salirutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. Salirumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of specifications200mg*2 bottles is priced around 17,500 per box (The price may fluctuate due to exchange rates). There are currently no generics of Salirumab produced in other countries.